Key facts
- This page summarizes ForGrowth NAP B.V.'s Form 4 filing for NewAmsterdam Pharma Co N.V. (NAMS).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 02 Jan 2025, 16:15.
ForGrowth NAP B.V. - 30 Dec 2024 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- NAMS
- Reported as of
- 30 Dec 2024
- Net transaction value
- -$762,174
- SEC form
- 4
- Accepted by SEC
- 02 Jan 2025, 16:15:04 UTC
- Prior SEC filing
- 30 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- FORGROWTH NAP B.V., By: Forbion International Management B.V., its Director, By: /s/ V. van Houten and /s/ G.J. Mulder, its Directors
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
ForGrowth NAP B.V. filed Form 4 for NewAmsterdam Pharma Co N.V. (NAMS) on 02 Jan 2025.
Change
- Previous filing in this sequence was filed on 30 Dec 2024.
- Current net transaction value: -$762,174.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NAMS
transaction
Ordinary Shares
Sale
- Transaction value
- -$762,174
- Shares
- -29,846
- Change %
- -0.28%
- Price
- $25.54
- Shares after
- 10,656,172
- Date
- 30 Dec 2024
- Ownership
- See footnote
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
ForGrowth NAP B.V. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by NAP PoolCo B.V. ("PoolCo") on March 28, 2024.
Footnote F2
Represents 13,108 shares sold on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. ("Forbion Growth I") and 16,738 shares sold on behalf of Forbion Capital Fund IV Cooperatief U.A. ("Forbion IV"). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.30 to $26.10.
Footnote F3
(Continued from footnote 2) The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Following the reported transaction, of the 10,656,172 Ordinary Shares beneficially owned by ForGrowth NAP B.V. ("ForGrowth"), 652,173 shares are directly owned by ForGrowth on behalf of Forbion Growth I, and 10,003,999 are held by PoolCo and are allocated to ForGrowth, of which 4,027,712 shares are beneficially owned by Forbion Growth I and 5,976,287 shares are beneficially owned by Forbion IV.
Footnote F4
ForGrowth is a shareholder of PoolCo. ForGrowth is a joint investment vehicle wholly owned by Forbion Growth I and Forbion IV but does not exercise voting or dispositive power over the Ordinary Shares held on behalf of Forbion Growth I and Forbion IV. Forbion IV Management B.V. is the sole director of Forbion IV and Forbion Growth Management B.V. is the sole director of Forbion Growth I. Each of the Reporting Persons disclaims Section 16 beneficial ownership of such shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such shares for Section 16 or any other purpose.